PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

EXPERIENCE PLUVICTO®

The first and only PSMA-targeted therapy, with ~30K patients treated since FDA approval[1,2,*]

Explore our commitment to a consistent, high-quality PLUVICTO experience for you and your patients

Indications

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

- PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

*Based on data from March 2026.[2]

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

WE ARE COMMITTED TO EXPANDING CAPACITY TO SERVE EVEN MORE PATIENTS

~30K
PATIENTS TREATED WITH PLUVICTO SINCE FDA APPROVAL[2,*]

With unconstrained supply, we've increased production for faster, on-time delivery of PLUVICTO to meet current and future demand

- There are **3 state-of-the-art manufacturing sites** for PLUVICTO in the United States (New Jersey, Indiana, and California), **with planned expansion to Florida and Texas**
- PLUVICTO can be **delivered within 5 days of order placement**,[†] so your patients can begin treatment as soon as possible[3]

~99.9%
ON-TIME DELIVERY FOR ALL PLUVICTO ORDERS[3]

~112K
DOSES SHIPPED FROM LAUNCH TO DATE[2,‡]

PRODUCT ORDERING SUPPORT IS AVAILABLE BY CALLING **1-844-367-3222**, MONDAY–FRIDAY, 6:00 AM–8:00 PM ET, EXCLUDING HOLIDAYS

*Based on data from March 2026.[2]

[†]Exceptions may apply for syringe form and select geographic locations.[3]

[‡]US commercial orders only.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

THE NUMBER OF PLUVICTO TREATMENT SITES CONTINUES TO GROW EACH YEAR

THERE ARE OVER
830
PLUVICTO TREATMENT SITES IN THE US[2]

~90% **OF PLUVICTO-ELIGIBLE PATIENTS ARE WITHIN 30 MILES OF A TREATMENT SITE[4,*]**

The number of treatment sites has been expanding, and PLUVICTO can now be administered in all 50 states and Puerto Rico

FIND A PLUVICTO TREATMENT CENTER ›

IF YOU'RE INTERESTED IN BECOMING A TREATMENT SITE, PLEASE CONTACT OUR CUSTOMER SUPPORT TEAM AT **1-844-367-3222**, MONDAY–FRIDAY, 6:00 AM–8:00 PM ET, EXCLUDING HOLIDAYS

This tool is updated in real time with the locations of additional treatment centers as well as the latest information, such as points of contact and insurances accepted. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on our website.

*Based on claims data and latest HCP location of patients as of March 2026.[2]

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

PLUVICTO IS ACCESSIBLE FOR MOST INSURED PATIENTS*

>80%

OF MEDICARE ELIGIBLE PATIENTS HAVE FAVORABLE COVERAGE FOR PLUVICTO[5,†]

>8 of 10

COVERED PATIENTS PAID $0 OUT-OF-POCKET PER INFUSION[6]

A review of claims data between Q1 2023-Q2 2024 indicated that approximately 85% of patients paid $0 for the product. For remaining patients, the out-of-pocket cost for the product varies and may be as high as the total cost of the product. Additional out-of-pocket costs may be incurred related to treatment, including but not limited to administration fees.

~98% PRIOR AUTHORIZATION APPROVAL RATE[7,‡]

QUESTIONS? CALL NOVARTIS PATIENT SUPPORT AT **1-844-638-7222**, MONDAY–FRIDAY, 8:00 AM–8:00 PM ET, EXCLUDING HOLIDAYS

ARPI, androgen receptor pathway inhibitor; PA, prior authorization.

***This is not a guarantee of coverage. Patient out-of-pocket costs may vary. Coverage and reimbursement decisions vary.**

†Coverage determined based on patients treated with at least one ARPI. The other 20% do not have published policies and/or cases may be determined on an individual basis. Follow up with the patient's plan to determine coverage.

‡Average PA approval rate for patients when enrolled through Novartis Patient Support.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

PATIENT ACCESS LOOKUP TOOL

Patient Access Lookup Tool

A tool to help you understand plan-specific patient coverage by state*

View insurance coverage for PLUVICTO

Download prior authorization forms and coverage summaries for PLUVICTO

Obtain payer contact information

GO TO THE PATIENT ACCESS LOOKUP TOOL ›

*This website provides general information and is not intended to provide reimbursement or legal advice. Furthermore, it is not intended to increase or maximize payment by any payer. Because laws, regulations, and coverage policies are complex and updated frequently, you should check with your local Medicare carrier and payers often or go to www.cms.gov.

Nothing in the information provided shall be construed as a guarantee of Novartis regarding levels of reimbursement, payment, or charge that reimbursement will be received. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your counsel or reimbursement specialist for any practice-specific reimbursement or billing questions.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

NOVARTIS PATIENT SUPPORT™ OFFERS A COMPREHENSIVE PROGRAM TO HELP ELIGIBLE PATIENTS START, STAY, AND SAVE ON PLUVICTO

Support tailored to referring providers and their patients:

1:1 Patient Navigation Support

Here to guide patients through the referral process, financial assistance, what to anticipate with treatment, and answers to common questions

Call **1-844-638-7222**
Monday–Friday, 8:00 AM–8:00 PM ET
to speak to a Novartis Patient Navigator

View the patient website coverage and support page

Find a PLUVICTO Treatment Center and information about their referral process

Novartis Patient Support works with treatment centers to update this list frequently to include helpful details and newly certified locations available

View the Treatment Center Locator

Referring Provider Support

Scan QR code and fax Start Form to **1-844-638-7329** to enroll

Our dedicated Novartis Patient Support team can help you navigate the referral process

- Benefit investigations in less than 2 days
- Referral follow-up with treatment centers for enrolled patients

View the Start Form

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

- PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.
- Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.
- Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation.
- To minimize radiation exposure to others, advise patients to limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days, to refrain from sexual activity for 7 days, and to sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

Myelosuppression

- PLUVICTO can cause severe and life-threatening myelosuppression. In clinical trials (PSMAddition, PSMAfore, VISION) grade 3 or 4 decreased hemoglobin (ranged from 4.3-15%), decreased leukocytes (4.4-7%), decreased neutrophils (3.5-4.5%), and decreased platelets (1.1-9%) occurred in patients treated with PLUVICTO. 5 myelosuppression-related deaths have occurred, including one due to bone marrow failure during long-term follow-up.
- Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of myelosuppression.

Renal Toxicity

- PLUVICTO can cause severe renal toxicity. In clinical trials grade 3 or 4 acute kidney injury (ranged from 1.3-3.4%) occurred in patients treated with PLUVICTO.
- Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearance (CrCl), before and during treatment. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of renal toxicity.

Embryo-Fetal Toxicity

- The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from PLUVICTO, can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

Infertility

- The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation-absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility

Adverse Reactions and Laboratory Abnormalities

- In the pooled safety population for the PSMAddition, PSMAfore and VISION studies (N=1320), the most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased lymphocytes (86%), decreased hemoglobin (68%), fatigue (51%), dry mouth (46%), decreased neutrophils (35%), nausea (35%), decreased platelets (33%), decreased estimated glomerular filtration rate (28%), increased aspartate aminotransferase (25%), decreased sodium (22%), increased magnesium (22%), increased potassium (21%), decreased calcium (21%), and increased alkaline phosphatase (20%).

Please see full Prescribing Information.

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. **2.** Data on file. NPS Numbers. Novartis Pharmaceuticals Corp; March 2026. **3.** Data on file. PLUVICTO NPS Metrics. Novartis Pharmaceuticals Corp; June 2025. **4.** Data on file. PLUVICTO Desert Analysis. Novartis Pharmaceuticals Corp; July 2025. **5.** Data on file. MMIT Market Access Claims. April 2026. **6.** Data on file. PLUVICTO IQVIA LAAD data analysis. Novartis Pharmaceuticals Corp; Jan 2023 to Jun 2024. **7.** Data on file. PLUVICTO NPS Metrics. Novartis Pharmaceuticals Corp; Jan 2025 to Dec 2025.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

WE ARE COMMITTED TO DELIVERING A CONSISTENT, HIGH-QUALITY PLUVICTO EXPERIENCE FOR YOU AND YOUR PATIENTS

PLUVICTO—the first and only PSMA-targeted therapy, with ~30K patients treated since FDA approval[1,2,*]

- There are over 833 PLUVICTO Treatment Centers in the US[2]
- PLUVICTO can be delivered within 5 days of order placement[3,†]

FIND A PLUVICTO TREATMENT CENTER ›

GO TO THE PATIENT ACCESS LOOKUP TOOL ›

Novartis Patient Support offers a comprehensive program to help eligible patients start, stay, and save on PLUVICTO

- Questions? Call Novartis Patient Support at **1-844-638-7222**, Monday–Friday, 8:00 AM–8:00 PM ET, excluding holidays

*Based on data from March 2026.[2]

†Exceptions may apply for syringe form and select geographic locations.[3]

Indications

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

- PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Please see additional Important Safety Information throughout and on pages 8-10 and accompanying full Prescribing Information.

NOVARTIS

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

6/26 FA-11654475